Endocyte, Inc. (NASDAQ:ECYT) announced that Scot L. Harper, Ph.D., Vice President of Clinical Operations, will be leaving the Company, effective October 28, 2016.  Clinical operations will be integrated with clinical development and report directly to Alison Armour, Chief Medical Officer. The Company has no current plans to replace the position of Vice President of Clinical Operations.

In connection with Dr. Harper’s departure and in consideration of his execution and non-revocation of a general release of claims in favor of the Company, Dr. Harper will be entitled to receive the severance and other benefits provided for under the terms of his existing severance agreement.